Pindolol

A beta-blocker blood pressure medicine, FDA-approved for hypertension.

psilodex.org/m/pindolol · data v2026.10.05

Clinical contraindication: None listed; No label contraindication covering psilocybin was found. This is not a finding that the combination has been shown to be without risk.
Psilocybin evidence: Other psychedelic; Human data with another classic psychedelic (e.g. LSD), not psilocybin; named in the text.
Half-life: ~3–4 h; Approximate, in adults. Source under Interaction below.

Named in state rules?

Not namedColorado Condition rules (3)

Not namedOregon

PendingNew Mexico

Cite asPsilodex, “Pindolol”, v2026.10.05. psilodex.org/m/pindolol

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

FDA-approved

Availability

Generic only in US

FDA-approved for

High blood pressure (hypertension)

Sources [1]

01 Interaction with psilocybin

With DMT, a related psychedelic, pindolol strengthened effects, so it may intensify psilocybin's effects. Separately, stopping it suddenly can worsen chest pain (angina).

Detail Pindolol is a beta-blocker that also blocks serotonin 5-HT1A receptors. In a human pretreatment study, pindolol significantly increased the psychological response to DMT (Strassman 1996). So it may intensify psilocybin's effects; there are no psilocybin data. It may also lessen psilocybin's heart-rate and blood pressure rise. Separately, abrupt stopping can worsen angina (chest pain). Sources [2]

Human data with psilocybin: None with psilocybin; human data with another psychedelic
Half-life: ~3–4 h (FDA label, checked 2026-10-04) About 7 h on average (up to 15 h) in elderly hypertensive patients.

Evidence types on this record

Other psychedelicHuman data with another classic psychedelic (e.g. LSD), not psilocybin; named in the text

02 Pharmacology relevant to psilocybin

3 listed · counted on reports

Withdrawal or rebound if stopped abruptly: Stopping suddenly can cause withdrawal or a rebound of symptoms. Sources [1]
Lowers blood pressure or causes orthostasis: Lowers blood pressure, or causes a drop on standing (orthostasis) that can bring dizziness or fainting. Sources [1]
Hypoglycemia risk: Can cause low blood sugar, especially if meals are missed or delayed. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not namedCondition rules (3)

No provision names this medication or its class.

Colorado · checked 2026-10-04

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-10-04

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-04

04 Conditions to ask about

Screening items in state rules

This medication is usually taken for a condition. State rules screen for some conditions directly, so the medication is a prompt to ask about them. Confirm with the participant; never assume a condition from the medication.

Hypertension (provision applies if uncontrolled)
- CO 2.5(A)(2) · Clinical Facilitator licensees
- CO 6.16(F)(2)(a) · Facilitators without a clinical facilitator license
- CO 6.16(F)(1) · All licensees

05 Sources

Pindolol Tablets USP (Sun Pharmaceutical) · FDA label (DailyMed) — Withdrawal or rebound if stopped abruptly: Warnings: Exacerbation of Ischemic Heart Disease Following Abrupt Withdrawal "Hypersensitivity to catecholamines has been observed in patients withdrawn from beta-blocker therapy; exacerbation of angina and, in some cases, myocardial infarction have occurred after abrupt discontinuation of such therapy." | Lowers blood pressure or causes orthostasis: Indications and Usage "Pindolol tablets are indicated in the management of hypertension." | Pharmacokinetics and Metabolism "The disposition of pindolol after oral administration is monophasic with a half-life in healthy subjects or hypertensive patients with normal renal function of approximately 3 to 4 hours." | revised 2026-03 | Warnings: Diabetes and Hypoglycemia: "Beta-adrenergic blockade may prevent the appearance of premonitory signs and symptoms (e.g., tachycardia and blood pressure changes) of acute hypoglycemia."
Strassman RJ. Human psychopharmacology of N,N-dimethyltryptamine. Behav Brain Res 1996;73(1-2):121–124. — Abstract: "To assess the role of the 5-HT1A site in mediating DMT's effects, a pindolol pre-treatment study was performed. Pindolol significantly increased psychological responses to DMT, suggesting a buffering effect of 5-HT1A agonism on 5-HT2-mediated psychedelic effects."

Record history

v2026.10.02First published.
2026-10-04Last reviewed against its sources.

Report an error in this record →